HHS Rebate Rule: At Least We Know Who Is In Charge

HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.

Azar_Alex_1902_400px.jpg
HHS Secretary Azar

It may be hard to predict what the elimination of the “safe harbor” that has allowed for prescription drug rebates in the US will mean for participants in the pharmaceutical supply chain, but the release of the rule makes one thing very clear: HHS Secretary Alex Azar intends to lead the drug pricing debate in 2019.

The rule, which would eliminate the protection on prescription drug rebates from prosecution under federal anti-kickback, will clearly have far-reaching...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

More from Government Payers